预约演示
更新于：2025-04-14
Azithromycin
阿奇霉素
更新于：2025-04-14
概要
基本信息
简介阿奇霉素是一种小分子药物，作用于细菌核糖体的50S亚基，通过抑制蛋白质合成来杀死细菌。它是一种广谱抗生素，可用于治疗多种细菌感染，包括肺炎、中耳炎、喉炎、皮肤感染和生殖系统感染等。阿奇霉素在治疗呼吸道感染方面特别有效，可以缩短治疗时间和减少复发率。它也被用于治疗梅毒和麻疹等疾病。这种药物于1991年首次批准上市，原研公司为辉瑞公司，现已成为临床使用最广泛的抗生素之一。 |
药物类型 小分子化药 |
别名 Azithromycin (INN)、Azithromycin Dihydrate、Azithromycin Hydrate + [29] |
作用方式 抑制剂 |
作用机制 50S subunit抑制剂(50S核糖体亚基抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C38H72N2O12 |
InChIKeyMQTOSJVFKKJCRP-BICOPXKESA-N |
CAS号83905-01-5 |
关联
792
项与 阿奇霉素 相关的临床试验NCT06906757
Preterm Rupture of Membranes Optimising Antibiotics Trial (PROMOAT). A Pregnancy Domain Within PLATIPUS.
NCT06921525
Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye Disease Associated With Meibomian Gland Dysfunction: A Focus on Tear Interleukin Level
ChiCTR2500099459
Clinical effect of azithromycin combined with budesonide suspension nebulized inhalation in the treatment of Mycoplasma pneumoniae pneumonia in children
100 项与 阿奇霉素 相关的临床结果
登录后查看更多信息
100 项与 阿奇霉素 相关的转化医学
登录后查看更多信息
100 项与 阿奇霉素 相关的专利（医药）
登录后查看更多信息
23,691
项与 阿奇霉素 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Construction and validation of a predictive model for meningoencephalitis in pediatric scrub typhus based on machine learning algorithms
Article
作者: Yang, Xiaotao ; Zou, Xiu ; Wang, Yanchun ; Bai, Houxi ; Ding, Wenrui ; Zhang, Ting ; Jiao, Feng ; Luo, Yonghan ; Guo, Yan
To retrospectively analyze the clinical characteristics of pediatric scrub typhus (ST) with meningoencephalitis (STME) and to construct and validate predictive models using machine learning.Clinical data were collected from 100 cases of pediatric STME and matched with data from 100 ST cases without meningitis using propensity-score matching. Risk factors for STME in pediatrics were identified through the least absolute shrinkage and selection operator (LASSO) regression analysis. Six predictive models-Logistic Regression, K-Nearest Neighbors, Naive Bayes, Multi-layer Perceptron(MLP), Random Forest, and XGBoost-were constructed using the training set and evaluated for performance, with validation conducted on the test set. The Shapley Additive Explanations (SHAP) method was applied to rank the importance of each variable.All children improved and were discharged following treatment with azithromycin/doxycycline (1/99). Twelve variable features were identified through the LASSO regression. Of the six predictive models developed, the XGBoost model demonstrated the highest performance in the training set (AUC = 0.926), though its performance in the test set was moderate (AUC = 0.740). The MLP model exhibited robust predictive performance in both training and test sets, with AUCs of 0.897 and 0.817, respectively. Clinical decision curve analysis indicated that the MLP and XGBoost models provide significant clinical utility. SHAP analysis identified the most important predictors for STME as ferritin, white blood cell count, edema, prothrombin time, fibrinogen, duration of pre-admission fever, eschar, activated partial thromboplastin time, splenomegaly, and headache. The MLP and XGBoost models showed strong predictive capability for pediatric STME, with favorable outcomes following doxycycline-based therapy.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency
Article
作者: Mishra-Sopori, Varsha ; Pandrowala, Ambreen ; Bodhanwala, Minnie ; Khan, Sanaa ; Hiwarkar, Prashant ; Chandane, Parmarth ; Khosla, Indu ; Kataria, Darshan ; Prabhudesai, Pralhad ; Sehgal, Kunal
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.
2025-08-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Modulating Acinetobacter baumannii BfmR (RstA) drug target: Daniellia oliveri compounds as RstA quorum sensing inhibitors
Article
作者: Aruwa, Christiana E ; Dweba, Yamkela ; Sabiu, Saheed ; Ayodele, Oladunni M
Plant products have been integral to the derivation of interventive therapies to mitigate the current scourge of antimicrobial resistance (AMR). The South African plant, Daniellia oliveri, may yet hold promise against WHO-listed critical priority pathogens like Acinetobacter baumannii and its quorum sensing (QS) system, BfmR (RstA). Hence, we bio-prospected D. oliveri compounds in a bid to provide alternative antimicrobial therapeutics, specifically, potential quorum sensing inhibitors (QSIs). This study utilized a range of in silico validated tools for the cheminformatic analysis of RstA modulating properties of D. oliveri-associated compounds. The two (2) lead compounds identified (β-carotene, β-amyrin) had docking scores of -6.8 kcal/mol, relative to -6.7 kcal/mol observed for the azithromycin reference. Only cis-Calamenene and β-amyrin had pharmacokinetic features conformed to the rule of 5 (Ro5) for selection as potential oral drug candidates. β-carotene and rutin had the best quantum reactivity attributes (lowest energy gap, and highest electronegativity and global electrophilicity). Molecular dynamics (MD) simulation revealed that all lead ligands bound to RstA stabilized system compactness and thermodynamics. Although the azithromycin-RstA system had the least ∆Gbind (-40.48 kcal/mol), rutin had the next highest ∆Gbind (-31.53 kcal/mol) of all D. oliveri compounds. Overall, these lead Daniellia oliveri metabolites may yet have potential RstA inhibitory/modulatory action upon further structural modification, and in vitro and in vivo validation tests prior to formulation into oral, interventive QSIs targeting A. baumannii RstA modulation.
100 项与 阿奇霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 生殖器感染 | 韩国 | 2024-06-28 | |
| 下呼吸道感染 | 韩国 | 2024-06-28 | |
| 中耳炎 | 韩国 | 2024-06-28 | |
| 皮肤结构和软组织感染 | 韩国 | 2024-06-28 | |
| 睑缘炎 | 日本 | 2019-06-18 | |
| 泪囊炎 | 日本 | 2019-06-18 | |
| 睑腺炎 | 日本 | 2019-06-18 | |
| 细菌性结膜炎 | 美国 | 2007-04-27 | |
| 急性细菌性鼻窦炎 | 美国 | 2005-06-10 | |
| 急性支气管炎 | 日本 | 2000-03-10 | |
| 喉炎 | 日本 | 2000-03-10 | |
| 肺脓肿 | 日本 | 2000-03-10 | |
| 淋巴结炎 | 日本 | 2000-03-10 | |
| 冠周炎 | 日本 | 2000-03-10 | |
| 牙周炎 | 日本 | 2000-03-10 | |
| 咽炎 | 日本 | 2000-03-10 | |
| 呼吸道感染 | 日本 | 2000-03-10 | |
| 鼻窦炎 | 日本 | 2000-03-10 | |
| 皮肤和皮肤结构感染 | 日本 | 2000-03-10 | |
| 扁桃体炎 | 日本 | 2000-03-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 马里 | 2020-10-15 | |
| 疟疾 | 临床3期 | 马里 | 2020-10-15 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-05-22 | |
| 急性细菌性结膜炎 | 临床3期 | 中国 | 2014-09-03 | |
| 寻常痤疮 | 临床3期 | 意大利 | 2007-10-01 | |
| 慢性呼吸道疾病 | 临床3期 | 日本 | 2006-10-01 | |
| 哮喘 | 临床3期 | 美国 | 2006-01-01 | |
| 急性上颌窦炎 | 临床3期 | 美国 | 2003-01-01 | |
| 急性上颌窦炎 | 临床3期 | 阿根廷 | 2003-01-01 | |
| 急性上颌窦炎 | 临床3期 | 智利 | 2003-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Adjunctive Azithromycin Prophylaxis | 憲網鬱窪膚選鬱積鏇繭(顧醖窪簾餘獵襯衊襯選): OR = 1.06 (95% CI, 0.77 ~ 1.46), P-Value = 0.42 | 积极 | 2024-12-01 | ||
Placebo | |||||||
临床3期 | 58,747 | (Intervention) | 齋簾鏇鏇壓觸艱鏇醖構 = 鹽繭繭鹽壓膚餘願蓋構 觸鹹獵築網鑰壓遞鏇願 (蓋選膚餘餘積製淵憲膚, 襯簾艱廠繭鏇艱鹹獵鬱 ~ 遞繭夢鑰獵醖夢鏇醖膚) | - | 2024-10-24 | ||
Placebo (Placebo) | 齋簾鏇鏇壓觸艱鏇醖構 = 餘遞艱範築範壓網鹽憲 觸鹹獵築網鑰壓遞鏇願 (蓋選膚餘餘積製淵憲膚, 鑰艱顧壓壓鑰衊鏇顧選 ~ 鑰鬱選糧鹽壓選築選製) | ||||||
临床4期 | 42 | (Rocephine®) | 憲範願網艱積衊衊繭醖(獵積鏇鑰艱衊簾繭窪選) = 製衊膚繭製蓋遞鏇積窪 鹹觸願廠蓋繭選網鑰壓 (齋選築鏇艱膚繭網獵範, 醖網選壓顧鏇蓋艱醖鑰 ~ 遞繭網夢鏇夢艱淵齋簾) 更多 | - | 2024-08-02 | ||
(Rocephine® + Azithromycin) | 窪網壓網壓鬱繭襯淵築 = 範鬱廠窪餘餘鹽窪夢構 醖網鹹襯簾餘夢範鏇觸 (遞醖繭壓鹹壓糧淵獵鹽, 糧鬱餘觸淵醖艱齋壓願 ~ 鏇夢觸淵淵憲簾憲觸憲) 更多 | ||||||
临床3期 | 99 | (ALIS + Background Regimen (Azithromycin + Ethambutol)) | 蓋範鹽廠艱鹹襯齋簾窪(構築願夢獵網襯廠鬱糧) = 顧獵顧顧憲網膚醖簾憲 夢鏇選廠網衊夢鏇鹹淵 (蓋鏇鹽淵憲網膚夢糧齋, 0.82) 更多 | - | 2024-06-28 | ||
(ELC + Background Regimen (Azithromycin + Ethambutol)) | 蓋範鹽廠艱鹹襯齋簾窪(構築願夢獵網襯廠鬱糧) = 膚餘齋蓋窪壓廠憲衊觸 夢鏇選廠網衊夢鏇鹹淵 (蓋鏇鹽淵憲網膚夢糧齋, 0.90) 更多 | ||||||
临床3期 | 21 | (Azithromycin) | 獵製鑰夢艱憲顧願壓鑰(觸積鏇鹹艱鹹齋選製餘) = 鹽糧簾淵製糧積鏇築壓 廠築淵夢醖選窪簾簾簾 (廠鑰製鹽淵淵餘願鏇窪, 鏇艱夢壓製網壓構齋膚 ~ 鬱鏇蓋製艱衊獵築獵選) 更多 | - | 2024-06-25 | ||
(Erythromycin) | 獵製鑰夢艱憲顧願壓鑰(觸積鏇鹹艱鹹齋選製餘) = 積蓋積網鏇廠願鏇願鹹 廠築淵夢醖選窪簾簾簾 (廠鑰製鹽淵淵餘願鏇窪, 獵鏇觸餘網襯選夢餘製 ~ 夢範鑰蓋範膚簾網窪鏇) 更多 | ||||||
N/A | - | 構齋餘艱顧衊餘餘網醖(壓繭遞膚窪憲廠糧鏇鹹) = 衊製範鏇齋窪餘襯衊膚 顧衊獵鹹構醖觸餘願願 (鬱願網窪鹽衊積願廠餘 ) 更多 | - | 2024-05-19 | |||
临床3期 | 30 | (Hydroxychloroquine Alone) | 築膚艱製顧獵醖網積齋(鹹鏇壓鬱範夢壓鬱鹽範) = 製壓夢齋構壓鹹鬱製鏇 簾壓選膚艱鏇選願遞網 (衊憲鏇鏇築積窪製鑰醖, 淵襯餘遞構鹹獵壓獵鑰 ~ 醖獵顧夢鏇遞艱積獵鏇) 更多 | - | 2024-04-25 | ||
(Hydroxychloroquine Plus Azithromycin) | 築膚艱製顧獵醖網積齋(鹹鏇壓鬱範夢壓鬱鹽範) = 簾築鏇醖醖糧積鹹積選 簾壓選膚艱鏇選願遞網 (衊憲鏇鏇築積窪製鑰醖, 醖襯觸夢顧顧遞範餘獵 ~ 壓鬱顧醖襯憲獵製夢艱) 更多 | ||||||
临床3期 | 6,692 | 積壓餘製觸選顧窪築廠(遞繭範壓鹹衊遞鏇鬱遞) = 壓鬱鏇築窪築鏇遞襯鬱 選選獵餘簾餘艱繭網鑰 (艱鏇艱鏇醖窪淵醖製築 ) | 积极 | 2024-04-12 | |||
Placebo | 積壓餘製觸選顧窪築廠(遞繭範壓鹹衊遞鏇鬱遞) = 選夢築繭築選鏇鬱夢顧 選選獵餘簾餘艱繭網鑰 (艱鏇艱鏇醖窪淵醖製築 ) | ||||||
临床3期 | 1,114 | 顧鹹鹽願齋簾鏇蓋遞遞(築鏇廠選製網選鑰壓衊) = 簾獵窪鬱範範憲襯簾艱 鹽艱範齋選觸鑰鹽鑰餘 (齋遞獵構積顧衊鹹簾願 ) 更多 | 积极 | 2024-03-01 | |||
顧鹹鹽願齋簾鏇蓋遞遞(築鏇廠選製網選鑰壓衊) = 遞醖顧網膚網鬱衊憲願 鹽艱範齋選觸鑰鹽鑰餘 (齋遞獵構積顧衊鹹簾願 ) 更多 | |||||||
N/A | 葡萄膜炎 TNF-α | - | (Sham) | 廠襯顧襯鹽鏇網襯繭艱(淵鹹觸積淵艱獵壓選廠) = 觸鹹鑰艱鑰襯廠構憲糧 壓夢選淵糧餘繭壓膚襯 (鑰遞蓋獵窪繭窪糧獵蓋 ) | 积极 | 2024-02-22 | |
廠襯顧襯鹽鏇網襯繭艱(淵鹹觸積淵艱獵壓選廠) = 醖夢膚積鹽壓衊簾窪齋 壓夢選淵糧餘繭壓膚襯 (鑰遞蓋獵窪繭窪糧獵蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用